|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHRNA5 |
Gene summary for CHRNA5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHRNA5 | Gene ID | 1138 |
| Gene name | cholinergic receptor nicotinic alpha 5 subunit | |
| Gene Alias | LNCR2 | |
| Cytomap | 15q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0001505 | UniProtAcc | P30532 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1138 | CHRNA5 | P2T-E | Human | Esophagus | ESCC | 4.29e-07 | 2.03e-01 | 0.1177 |
| 1138 | CHRNA5 | P4T-E | Human | Esophagus | ESCC | 1.01e-24 | 7.40e-01 | 0.1323 |
| 1138 | CHRNA5 | P5T-E | Human | Esophagus | ESCC | 9.79e-12 | 3.00e-01 | 0.1327 |
| 1138 | CHRNA5 | P8T-E | Human | Esophagus | ESCC | 6.56e-03 | 7.03e-02 | 0.0889 |
| 1138 | CHRNA5 | P10T-E | Human | Esophagus | ESCC | 2.18e-04 | 9.53e-02 | 0.116 |
| 1138 | CHRNA5 | P11T-E | Human | Esophagus | ESCC | 7.58e-04 | 3.43e-01 | 0.1426 |
| 1138 | CHRNA5 | P12T-E | Human | Esophagus | ESCC | 3.52e-09 | 2.48e-01 | 0.1122 |
| 1138 | CHRNA5 | P15T-E | Human | Esophagus | ESCC | 1.78e-07 | 1.15e-01 | 0.1149 |
| 1138 | CHRNA5 | P16T-E | Human | Esophagus | ESCC | 8.56e-18 | 4.84e-01 | 0.1153 |
| 1138 | CHRNA5 | P20T-E | Human | Esophagus | ESCC | 8.97e-05 | 6.85e-02 | 0.1124 |
| 1138 | CHRNA5 | P21T-E | Human | Esophagus | ESCC | 1.57e-03 | 5.52e-02 | 0.1617 |
| 1138 | CHRNA5 | P22T-E | Human | Esophagus | ESCC | 6.47e-10 | 1.50e-01 | 0.1236 |
| 1138 | CHRNA5 | P23T-E | Human | Esophagus | ESCC | 1.31e-08 | 1.14e-01 | 0.108 |
| 1138 | CHRNA5 | P26T-E | Human | Esophagus | ESCC | 1.38e-13 | 2.57e-01 | 0.1276 |
| 1138 | CHRNA5 | P27T-E | Human | Esophagus | ESCC | 3.63e-06 | 1.45e-01 | 0.1055 |
| 1138 | CHRNA5 | P28T-E | Human | Esophagus | ESCC | 5.28e-14 | 2.55e-01 | 0.1149 |
| 1138 | CHRNA5 | P30T-E | Human | Esophagus | ESCC | 1.39e-12 | 2.87e-01 | 0.137 |
| 1138 | CHRNA5 | P31T-E | Human | Esophagus | ESCC | 9.03e-09 | 2.26e-01 | 0.1251 |
| 1138 | CHRNA5 | P32T-E | Human | Esophagus | ESCC | 4.51e-15 | 3.28e-01 | 0.1666 |
| 1138 | CHRNA5 | P36T-E | Human | Esophagus | ESCC | 7.70e-04 | 2.54e-01 | 0.1187 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHRNA5 | SNV | Missense_Mutation | c.464N>G | p.Asn155Ser | p.N155S | P30532 | protein_coding | tolerated(0.11) | benign(0.174) | TCGA-A2-A0T1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | herceptin | SD | |
| CHRNA5 | SNV | Missense_Mutation | novel | c.264N>C | p.Glu88Asp | p.E88D | P30532 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CHRNA5 | SNV | Missense_Mutation | c.456C>G | p.Ile152Met | p.I152M | P30532 | protein_coding | deleterious(0.02) | benign(0.143) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CHRNA5 | SNV | Missense_Mutation | novel | c.330G>T | p.Trp110Cys | p.W110C | P30532 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHRNA5 | SNV | Missense_Mutation | c.761C>A | p.Thr254Asn | p.T254N | P30532 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CHRNA5 | SNV | Missense_Mutation | c.1180N>C | p.Glu394Gln | p.E394Q | P30532 | protein_coding | tolerated(0.28) | benign(0.038) | TCGA-C5-A7CH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | SD | ||
| CHRNA5 | SNV | Missense_Mutation | c.627N>C | p.Lys209Asn | p.K209N | P30532 | protein_coding | tolerated(0.11) | possibly_damaging(0.872) | TCGA-DS-A0VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CHRNA5 | SNV | Missense_Mutation | novel | c.1224N>A | p.Met408Ile | p.M408I | P30532 | protein_coding | deleterious(0.01) | benign(0.033) | TCGA-UC-A7PG-06 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
| CHRNA5 | SNV | Missense_Mutation | novel | c.820N>T | p.Leu274Phe | p.L274F | P30532 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CHRNA5 | SNV | Missense_Mutation | rs775819304 | c.743N>A | p.Arg248His | p.R248H | P30532 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1138 | CHRNA5 | DRUGGABLE GENOME, ION CHANNEL | partial agonist | CHEMBL127071 | POZANICLINE | |
| 1138 | CHRNA5 | DRUGGABLE GENOME, ION CHANNEL | antagonist | 178100835 | ||
| 1138 | CHRNA5 | DRUGGABLE GENOME, ION CHANNEL | ethanol | ALCOHOL | ||
| 1138 | CHRNA5 | DRUGGABLE GENOME, ION CHANNEL | Drugs used in nicotine dependence | 25950378 | ||
| 1138 | CHRNA5 | DRUGGABLE GENOME, ION CHANNEL | Opium alkaloids and derivatives | 20725741 | ||
| 1138 | CHRNA5 | DRUGGABLE GENOME, ION CHANNEL | antagonist | 178100837 | ||
| 1138 | CHRNA5 | DRUGGABLE GENOME, ION CHANNEL | cocaine | COCAINE | 32152934 | |
| 1138 | CHRNA5 | DRUGGABLE GENOME, ION CHANNEL | antagonist | 178100808 | ||
| 1138 | CHRNA5 | DRUGGABLE GENOME, ION CHANNEL | cotinine | COTININE | ||
| 1138 | CHRNA5 | DRUGGABLE GENOME, ION CHANNEL | antagonist | 178100796 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |